Tropane analogs and methods for inhibition of monoamine transport
View Patent ↗New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7-hydroxyl or ketone substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
1. A compound having the structural formula:
wherein:
R 1 =COR 3 , and is α or β;
R 2 =OH or O, is a 6- or 7-substituent, and if R 2 is OH, it is α or β;
X=NR 3 or NSO 2 R 3 , with the N being a member of the ring;
R 3 =H, (CH 2 ) n C 6 H 4 Y, C 6 H 4 Y, CHCH 2 , lower alkyl, lower alkenyl or lower alkynyl;
Y=H, Br, Cl, I, F, OH, OCH 3 , CF 3 , NO 2 , NH 2 , CN, NHCOCH 3 , N(CH 3 ) 2 , (CH 2 ) n CH 3 , COCH 3 , or C(CH 3 ) 3 ;
Ar=phenyl-R 5 , naphthyl-R 5 , anthracenyl-R 5 , phenanthrenyl-R 5 , or diphenylmethoxy-R 5 ;
R 5 =H, Br, Cl, I, F, OH, OCH 3 , CF 3 , NO 2 , NH 2 , CN, NHCOCH 3 , N(CH 3 ) 2 , (CH 2 )nCH 3 , COCH 3 , C(CH 3 ) 3 where n=0–6, 4-F, 4-Cl, 4-I, 2-F, 2-Cl, 2-I, 3-F, 3-Cl, 3-I, 3,4-diCl, 3,4-diOH, 3,4-diOAc, 3,4-diOCH 3 , 3-OH-4-C, 3-OH-4-F, 3-Cl-4-OH, 3-F-4-OH, lower alkyl, lower alkoxy, lower alkenyl, lower alkynyl, CO(lower alkyl), or CO(lower alkoxy); and
n=0, 1, 2, 3, 4 or 5.
2. The compound of claim 1 , which is a 1-S enantiomer.
3. The compound of claim 1 , wherein Ar is a 3α-group.
4. The compound of claim 1 , wherein Ar is a 3β-group.
5. The compound of claim 1 , wherein R 2 is OH, and X is NR 3 .
6. The compound of claim 1 , wherein wherein the compound has an IC 50 SERT/DAT ratio of greater than about 10, preferably greater than about 30 and more preferably 50 or more.
7. The compound of claim 1 , having an IC 50 at the DAT of less than about 500 nM, preferably less than 60 nM, more preferably less than about 20, and most preferably less than about 10.
8. The compound of claim 1 , wherein X is NR 3 or NSO 2 R 2 , and Ar is phenyl, substituted phenyl, diarylmethoxy or subsituted diarlymethoxy.
9. The compound of claim 8 , wherein the substitutent is a halogen.
10. The compound of claim 8 , wherein the AR is a mono- or di-halogen substituted phenyl.
11. The compound of claim 1 , wherein the aryl ring is substituted with one or more halide atoms, hydroxy groups, nitro groups, amino groups, cyano groups, lower alkyl groups having from 1–8 carbon atoms, lower alkoxy groups having from 1–8 carbon atoms, lower alkenyl groups having from 2–8 carbon atoms, or lower alkynyl groups having from 2–8 carbon atoms.
12. The compound of claim 11 , wherein the aryl ring can be substituted with chloride, fluoride or iodide.
13. The compound of claim 11 , wherein an amino group is a mono- or di-alkyl substituted group having from 1–8 carbon atoms.
14. The compound of claim 11 , wherein the aryl group has a substituent selected from the group consisting of Br, Cl, I, F, OH, OCH 3 , CF 3 , NO 2 , NH 2 , CN, NHCOCH 3 , N(CH 3 ) 2 , COCH 3 , C(CH 3 ) 3 , (CH 2 ) n CH 3 where n=0–6, allyl, isopropyl and isobutyl.
15. The compound of claim 1 , wherein the aryl group has a substituent selected from the group consisting of lower alkyl, lower alkenyl and lower alkynyl.
16. The compound of claim 1 , wherein the aryl group is substituted with a member of the group consisting of 4-F, 4-Cl, 4-I, 2-F, 2-Cl, 2-I, 3-F, 3-Cl, 3-I, 3,4-diCl, 3,4-diOH, 3,4-diOAc, 3,4-diOCH 3 , 3-OH-4-Cl, 3-OH-4-F, 3-Cl-4-OH and 3-F-4-OH.
17. The compound of claim 8 , wherein R 2 is OH.
18. The compound of claim 1 having the following structural formula:
where X is NR 3 , R 3 is CH 2 CH 3 , R 2 is OH or O in the 6- or 7-position, Ar is phenyl or naphthyl either of which can be substituted with halogen, alkenyl having 2–8 carbon atoms or alkynyl having 2–8 carbon atoms.
19. The compound of claim 18 , wherein Ar is substituted with 4-Cl, 4-F, 4-Br, 4-I, 3,4-Cl 2 , ethenyl, propenyl, butenyl, propynyl or butynyl.
20. The compound of claim 18 , wherein R 2 is OH.
21. The compound of claim 18 selected from the group consisting of:
a. 1-[3α-(3,4-Dichlorophenyl)-7β-hydroxy-8-methyl-8-azabicyclo[3.2.1]oct-2-yl]propan-1-one,
b. 1-[3β-(3,4-Dichlorophenyl)-7β-hydroxy-8-methyl-8-azabicyclo[3.2.1]oct-2-yl]propan-1-one.
22. The compound of claim 1 selected from the group consisting of:
a. 1-[3α-(3,4-Dichlorophenyl)-7β-hydroxy-8-methyl-8-azabicyclo[3.2.1]oct-2-yl]propan-1-one;
b. 1-[3β-(3,4-Dichlorophenyl)-7β-hydroxy-8-methyl-8-azabicyclo[3.2.1]oct-2-yl]propan-1-one.
23. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
24. A compound having the structural formula:
wherein:
R 1 =COR 3 , CON(R 7 )OR 7 and is α or β;
R 2 =OR 9 and is a 6- or 7-substituent;
R 3 =H, (CH 2 ) n C 6 H 4 Y, C 6 H 4 Y, CHCH 2 , lower alkyl, lower alkenyl or lower alkynyl;
Y=H, Br, Cl, I, F, OH, OCH 3 , CF 3 , NO 2 , NH 2 , CN, NHCOCH 3 , N(CH 3 ) 2 , (CH 2 ) n CH 3 , COCH 3 , or C(CH 3 ) 3 ;
R8=camphanoyl, phenyl-R 5 , naphthyl-R 5 , anthracenyl-R 5 , phenanthrenyl-R 5 , or diphenylmethoxy-R 5 ;
R 5 =H, Br, Cl, I, F, OH, OCH 3 , CF 3 , NO 2 , NH 2 , CN, NHCOCH 3 , N(CH 3 ) 2 , (CH 2 )nCH 3 , COCH 3 , C(CH 3 ) 3 where n=0–6, 4-F, 4-Cl, 4-I, 2-F, 2-Cl, 2-I, 3-F, 3-Cl, 3-I, 3,4-diCl, 3,4-diOH, 3,4-diOAc, 3,4-diOCH 3 , 3-OH-4-Cl, 3-OH-4-F, 3-Cl-4-OH, 3-F-4-OH, lower alkyl, lower alkoxy, lower alkenyl, lower alkynyl, CO(lower alkyl), or CO(lower alkoxy);
n=0, 1, 2, 3, 4 or 5;
R 7 =lower alkyl; and
R9=a protecting group.
25. The compound of claim 24 selected from the group consisting of:
a) 2β-Carbo-N-methoxy-N-methylamino-3α-(3,4-dichlorophenyl)-7β-methoxymethoxy-8-methyl-8-azabicyclo[3.2.1]octane;
b) 2β-Carbo-N-methoxy-N-methylamine-3β-(3,4-dichlorophenyl)-7β-methoxymethoxy-8-methyl-8-azabicyclo[3.2.1]octane;
c) 1-[3α-(3,4-Dichlorophenyl)-7β-methoxymethoxy-8-methyl-8-azabicyclo[3.2.1]oct-2-yl]propan-1-one;
d) 1-[3β-(3,4-Dichlorophenyl)-7β-methoxymethoxy-8-methyl-8-azabicyclo[3.2.1]oct-2-yl]propan-1-one.
26. A compound having the structural formula:
wherein:
R 1 =COOR 7 , COR 3 , lower alkyl, lower alkenyl, lower alkynyl, CONHR 4 , or COR 6 and is α or β;
R 2 =O and is a 6- or 7-substituent;
X=NR 3 , with the N being a member of the ring;
R 3 =H, (CH 2 ) n C 6 H 4 Y, C 6 H 4 Y, CHCH 2 , lower alkyl, lower alkenyl or lower alkynyl;
Y=H, Br, Cl, I, F, OH, OCH 3 , CF 3 , NO 2 , NH 2 , CN, NHCOCH 3 , N(CH 3 ) 2 , (CH 2 ) n CH 3 , COCH 3 , or C(CH 3 ) 3 ;
R 4 =CH 3 , CH 2 CH 3 , or CH 3 SO 2 ;
R 6 =morpholinyl or piperidinyl;
Ar=phenyl-R 5 , naphthyl-R 5 , anthracenyl-R 5 , phenanthrenyl-R 5 , or diphenylmethoxy-R 5 ;
R 5 =H, Br, Cl, I, F, OH, OCH 3 , CF 3 , NO 2 , NH 2 , CN, NHCOCH 3 , N(CH 3 ) 2 , (CH 2 )nCH 3 , COCH 3 , C(CH 3 ) 3 where n=0–6, 4-F, 4-Cl, 4-I, 2-F, 2-Cl, 2-I, 3-F, 3-Cl, 3-I, 3,4diCl, 3,4-diOH, 3,4-diOAc, 3,4-diOCH 3 , 3-OH-4-F, 3-Cl-4-OH, 3-F-4-OH, lower alkyl, lower alkoxy, lower alkenyl, lower alkynyl, CO(lower alkyl), or CO(lower alkoxy);
n=0, 1, 2, 3, 4 or 5; and
R 7 =lower alkyl.
27. The compound of claim 26 , which is a 1-S enantiomer.
28. The compound of claim 26 , wherein Ar is a 3α-group.
29. The compound of claim 26 , wherein Ar is a 3β-group.